Cytokinetics (NASDAQ:CYTK – Get Free Report) and Tempest Therapeutics (NASDAQ:TPST – Get Free Report) are both healthcare companies, but which is the superior stock? Get Cytokinetics alerts:Institutional and Insider Ownership22.5% of Tempest Therapeutics shares are owned by institutional investors. Analyst RatingsThis is a summary of current ratings and price targets for Cytokinetics and Tempest Therapeutics, as provided by MarketBeat. Given Cytokinetics’ stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Tempest Therapeutics. Net Margins Return on Equity Return on Assets Cytokinetics -784.02% N/A -52.86% Tempest Therapeutics N/A -355.61% -121.21%SummaryCytokinetics beats Tempest Therapeutics on 8 of the 14 factors compared between the two stocks.